Company Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.
The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease.
The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| Founded | 1976 |
| IPO Date | Feb 9, 1989 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,050 |
| CEO | Kim Kelderman |
Contact Details
Address: 614 McKinley Place N.E. Minneapolis, Minnesota 55413 United States | |
| Phone | 612 379 8854 |
| Website | bio-techne.com |
Stock Details
| Ticker Symbol | TECH |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000842023 |
| CUSIP Number | 09073M104 |
| ISIN Number | US09073M1045 |
| Employer ID | 41-1427402 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kim Kelderman | Chief Executive Officer, President and Director |
| James T. Hippel CPA | Executive Vice President of Finance and Chief Financial Officer |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary and Chief Sustainability Officer |
| William A. Geist | President of Protein Sciences Segment |
| Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics and Genomics |
| Dr. Gary J. Latham Ph.D. | Vice President and Chief Technology Officer |
| David Clair C.F.A. | Senior Director of Investor Relations and Corporate Development |
| Gerry Andros | Vice President of Sales and Marketing |
| Martin Wirtz | Senior Vice President of Strategy and Corporate Development |
| Cheryl Bethune | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 12, 2024 | ARS | Filing |
| Sep 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 12, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 22, 2024 | 10-K | Annual Report |